Obesity

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical organizations to speak out about safety concerns.

The prevalence of obesity and diabetes has grown worldwide, presenting notable challenges to public health and health care systems.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.

Intentional weight loss of 5% or more, coupled with reduced waist circumference was associated with lower risk for death from cancer, CVD or any cause among postmenopausal women followed for more than 18 years, data show.

The U.S. Preventive Services Task Force ruled that there is insufficient evidence to recommend for or against screening for food insecurity in primary care.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial.

Slightly elevated blood glucose within a range of what is generally considered “normal” may be associated with increased risk for heart disease, researchers reported.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.

Obesity prevalence increased among both adults and children across all regions of the world from 1990 to 2021, and more than half of adults are expected to have obesity by 2050, according to two reports published in The Lancet.

Glucagon-like peptide-1 receptor agonists, an increasingly popular class of weight loss medications, have been found to be associated with new onset acne in women, according to a research letter published in Journal of the American Academy of Dermatology.